SCO-267 is an allosteric GPR40 full agonist. SCO-267 can be used for the research of chronic diseases including diabetes In Vitro SCO-267 (CHO cells) activates the Gα q , Gα s , and Gα 12/13 pathways and β-Arrestin Recruitment. SCO-267 is allosteric with fasiglifam and an endogenous ligand. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo SCO-267 (1 or 10 mg/kg; p.o.) improves insulin sensitivity and exerts sustained glucose-lowering effect . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: N-STZ rats Dosage: 1 or 10 mg/kg Administration: P.o.; Result: Improved insulin sensitivity and exerted sustained glucose-lowering effect. Form:Solid IC50& Target:GPR40